Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xiamen Yidaokang Pharmaceutical is a China-based biopharmaceutical company dedicated to the research, development, and commercialization of innovative small molecule drugs. The company primarily focuses on metabolic and cardiovascular diseases, with a lead program targeting Type 2 Diabetes through SGLT2 inhibition. Headquartered in Xiamen, Fujian, the firm leverages its R&D platform to advance a pipeline of candidates aimed at addressing significant unmet medical needs in the chronic disease space. Their business model encompasses the full lifecycle of drug development from discovery to manufacturing. The company is recognized for its Class 1 innovative drug candidates within the Chinese regulatory framework.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Xiamen Yidaokang Pharmaceutical.